Inspira Technologies Signs Letter Of Intent With Northwestern Memorial Hospital In Chicago For Clinical Use Of INSPIRA ART100 Device
Portfolio Pulse from Benzinga Newsdesk
Inspira Technologies (NASDAQ:IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital for the clinical use of its INSPIRA ART100 device, pending FDA clearance. The collaboration will involve Northwestern purchasing disposables for the device and providing usage data to Inspira Technologies. The agreement is contingent on FDA approval expected in the first half of 2024 and a definitive evaluation agreement.
January 02, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inspira Technologies may see positive investor sentiment due to the LOI with a top-ranked hospital for its INSPIRA ART100 device, subject to FDA clearance.
The LOI with a prestigious hospital like Northwestern Memorial could be seen as a validation of Inspira Technologies' product, potentially leading to increased investor confidence. However, the impact is moderated by the fact that the agreement is non-binding and contingent on FDA clearance.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 100